keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/28943900/influence-of-chronic-inflammation-on-bcl-2-and-pcna-expression-in-prostate-needle-biopsy-specimens
#1
Michael Glover, Shardul Soni, Qinghu Ren, Gregory T Maclennan, Pingfu Fu, Sanjay Gupta
The association between inflammation and cancer has been established in certain forms of human malignancies; however, its role in prostate cancer remains unclear. The present study investigates a possible association between chronic inflammation and the development of epithelial neoplasia in the prostate. Needle biopsy specimens were obtained from patients with serum prostate-specific antigen levels >4 ng/ml, evaluated for morphological findings, and immunostained for Bcl-2 and proliferating cell nuclear antigen (PCNA)...
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28942009/comparison-of-11-active-surveillance-protocols-in-contemporary-european-men-treated-with-radical-prostatectomy
#2
Sami-Ramzi Leyh-Bannurah, Pierre I Karakiewicz, Paolo Dell'Oglio, Alberto Briganti, Jonas Schiffmann, Raisa S Pompe, Guido Sauter, Thorsten Schlomm, Hans Heinzer, Hartwig Huland, Markus Graefen, Lars Budäus
BACKGROUND: The aim of this study was to compare 11 active surveillance (AS) protocols in contemporary European men treated with radical prostatectomy (RP) at the Martini-Clinic Prostate Cancer Center. PATIENTS AND METHODS: Analyzed were 3498 RP patients, from 2005 to 2016, who underwent ≥ 10 core biopsies and fulfilled at least 1 of 11 examined AS entry definitions. We tested proportions of AS eligibility, ineligibility, presence of primary Gleason 4/5, upstage, and combinations thereof at RP, as well as 5-year biochemical recurrence-free survival (BFS)...
August 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28941922/the-association-of-polymorphisms-in-the-gene-encoding-gonadotropin-releasing-hormone-with-serum-testosterone-level-during-androgen-deprivation-therapy-and-prognosis-in-metastatic-prostate-cancer
#3
Masaki Shiota, Naohiro Fujimoto, Ario Takeuchi, Eiji Kashiwagi, Takashi Dejima, Junichi Inokuchi, Katsunori Tatsugami, Akira Yokomizo, Shunichi Kajioka, Takeshi Uchiumi, Masatoshi Eto
PURPOSE: Serum testosterone suppression during androgen-deprivation therapy (ADT) has been reported to affect ADT efficacy. However, the factors impacting hormonal variations during ADT remain unclear. Therefore, in this study, we investigated the significance of missense polymorphisms in the gene encoding gonadotropin releasing hormone (GNRH) in men treated with primary ADT for metastatic prostate cancer. MATERIALS AND METHODS: This study included 80 Japanese patients with metastatic prostate cancer whose serum testosterone levels during ADT were available...
September 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28941016/ethyl-acetate-fraction-from-methanol-extraction-of-vitis-thunbergii-var-taiwaniana-induced-g0-g1-phase-arrest-via-inhibition-of-cyclins-d-and-e-and-induction-of-apoptosis-through-caspase-dependent-and-independent-pathways-in-human-prostate-carcinoma-du145-cells
#4
Chia-Hsin Lin, Hsiao-Sung Chan, Hsin-Sheng Tsay, Shinji Funayama, Chao-Lin Kuo, Jing-Gung Chung
Vitis thunbergii var. taiwaniana (VTT) is a wild grape native to Taiwan, belonging to the Vitaceae family and Vitis genus, and widely used as folk herbal medicine. It is traditionally used for the treatment of diarrhea, hypertension, neuroprotection, jaundice, and arthritis. We used the wild-collected VTT and sterilized them to establish the plant tissue culture, and then took the leaves for DNA sequencing to determine its original base. We use methanol to extract VTT in four different solvents: 1-butanol, n-hexane, ethyl acetate, and water...
September 22, 2017: Environmental Toxicology
https://www.readbyqxmd.com/read/28940952/real-world-uptake-safety-profile-and-outcomes-of-docetaxel-in-newly-diagnosed-metastatic-prostate-cancer
#5
Robert Rulach, Stephen McKay, Sam Neilson, Lillian White, Jan Wallace, Ross Carruthers, Carolynn Lamb, Almudena Cascales, Husam Marashi, Hilary Glen, Balaji Venugopal, Azmat Sadoyze, Norma Sidek, J Martin Russell, Abdulla Alhasso, David Dodds, Jennifer Laskey, Robert J Jones, Nicholas MacLeod
OBJECTIVES: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical trial. SUBJECTS/PATIENTS AND METHODS: Patients in the West of Scotland Cancer Network (WoSCAN) with newly diagnosed mPC were identified from the regional multidisciplinary team (MDT) meetings and their treatment details were collected from electronic patient records. The rate of febrile neutropenia, hospitalisations, time to progression and overall survival were compared between those patients who received docetaxel and androgen deprivation therapy (ADT), or ADT alone using survival analysis...
September 20, 2017: BJU International
https://www.readbyqxmd.com/read/28939825/mitochondrial-mutations-drive-prostate-cancer-aggression
#6
Julia F Hopkins, Veronica Y Sabelnykova, Joachim Weischenfeldt, Ronald Simon, Jennifer A Aguiar, Rached Alkallas, Lawrence E Heisler, Junyan Zhang, John D Watson, Melvin L K Chua, Michael Fraser, Francesco Favero, Chris Lawerenz, Christoph Plass, Guido Sauter, John D McPherson, Theodorus van der Kwast, Jan Korbel, Thorsten Schlomm, Robert G Bristow, Paul C Boutros
Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age...
September 22, 2017: Nature Communications
https://www.readbyqxmd.com/read/28939004/the-phase-3-cou-aa-302-study-of-abiraterone-acetate-plus-prednisone-in-men-with-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-stratified-analysis-based-on-pain-prostate-specific-antigen-and-gleason-score
#7
Kurt Miller, Joan Carles, Jürgen E Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D Brookman-May
BACKGROUND: In the COU-AA-302 study (NCT00887198), abiraterone acetate plus prednisone (AAP) significantly improved outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) versus prednisone alone. Baseline clinical parameters predicting that treatment response could help inform clinical decisions were explored. OBJECTIVE: To identify patients who derive the greatest clinical benefit from AAP treatment. DESIGN, SETTING, AND PARTICIPANTS: A total of 1088 mCRPC patients treated with either AAP or prednisone in the first-line setting in COU-AA-302 were included in this post hoc analysis...
September 19, 2017: European Urology
https://www.readbyqxmd.com/read/28938674/network-meta-analysis-of-the-efficacy-and-adverse-effects-of-several-treatments-for-advanced-metastatic-prostate-cancer
#8
Jing Wu, Wei-Kang Chen, Wei Zhang, Jin-Song Zhang, Jian-He Liu, Yong-Ming Jiang, Ke-Wei Fang
This network meta-analysis was conducted to compare the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer (PC). The PubMed and Cochrane Library databases were searched for randomized controlled trials of treatments for advanced/metastatic PC. Eighteen studies covering 6,340 patients were included in this analysis. The calculated were odds ratios, 95% confidence intervals, and the surface under the cumulative ranking (SUCRA) curve. Pairwise meta-analysis showed that overall survival rates achieved with radiotherapy or endocrine therapy were lower than obtained with radiotherapy + endocrine therapy...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938672/comparing-the-clinical-efficacy-of-abiraterone-acetate-enzalutamide-and-orteronel-in-patients-with-metastatic-castration-resistant-prostate-cancer-by-performing-a-network-meta-analysis-of-eight-randomized-controlled-trials
#9
Minyong Kang, Chang Wook Jeong, Cheol Kwak, Ja Hyeon Ku, Hyeon Hoe Kim
Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable oncological outcomes. Here, we aimed to compare the efficacy of novel AR-targeted agents by performing a network meta-analysis of randomized controlled trials (RCTs). We included eight RCTs for men with mCRPC treated with one of the AR targeting agents: abiraterone acetate, enzalutamide, or orteronel...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938627/prostate-tumor-overexpressed-1-ptov1-promotes-docetaxel-resistance-and-survival-of-castration-resistant-prostate-cancer-cells
#10
Verónica Cánovas, Yolanda Puñal, Valentina Maggio, Enric Redondo, Mercedes Marín, Begoña Mellado, Mireia Olivan, Matilde Lleonart, Jacques Planas, Juan Morote, Rosanna Paciucci
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. Here, we investigated the role of PTOV1 in prostate cancer survival to docetaxel and self-renewal ability. Transduction of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell survival after docetaxel exposure and induced docetaxel-resistance genes expression (ABCB1, CCNG2 and TUBB2B)...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28937454/life-expectancy-and-metastatic-spine-scoring-systems-an-academic-institutional-experience
#11
Brian T Ragel, Gustavo A Mendez, Justin Reddington, David Ferachi, Charlotte D Kubicky, Travis C Philipp, Natalie L Zusman, Paul Klimo, Robert Hart, Jung Yoo, Alex C Ching
STUDY DESIGN: A retrospective data collection study with application of metastatic spine scoring systems. OBJECTIVES: To apply the Tomita and revised Tokuhashi scoring systems to a surgical cohort at a single academic institution and analyze spine-related surgical morbidity and mortality rates. SUMMARY OF BACKGROUND DATA: Surgical management of metastatic spine patients requires tools that can accurately predict patient survival, as well as knowledge of morbidity and mortality rates...
October 2017: Clinical Spine Surgery
https://www.readbyqxmd.com/read/28936267/roles-of-kallikrein-2-biomarkers-free-hk2-and-pro-hk2-for-predicting-prostate-cancer-progression-free-survival
#12
Anatilde Gonzalez Guerrico, David Hillman, Jeffery Karnes, Brian Davis, Steven Gaston, George Klee
Free human kallikrein 2 (free-hK2) and hK2 pro-form (pro-hK2) have been found to be increased in tumor tissues and serum from patients with prostate cancer. We established semiautomatic assays for free-hK2 and pro-hK2 using a research version of the Beckman Coulter ACCESS2 system. Serum samples from a cohort of 189 men undergoing radical prostatectomy for known high-risk disease were assayed for Prostate-Specific Antigen (PSA), free-PSA, free-hK2, and pro-hK2. Univariate Cox regression and multivariate models were used to predict both Gleason scores and progression-free survival (PFS)...
January 2017: J Circ Biomark
https://www.readbyqxmd.com/read/28935774/immunotherapy-a-new-and-old-approach-to-treatment-of-soft-tissue-and-bone-sarcomas
#13
REVIEW
Michael J Nathenson, Anthony P Conley, Edward Sausville
Soft tissue and bone sarcomas are a rare and heterogeneous form of cancer. With standard of care treatment options including surgery, radiation, and chemotherapy, the long-term survival is still low for high-risk soft tissue sarcoma patients. New treatment strategies are needed. Immunotherapy offers a new potential treatment paradigm with great promise. Immunotherapy of soft tissue sarcomas dates back to Dr. Coley's first use of toxins in the late 1800s. A variety of strategies of immunotherapy have been tried in soft tissue and bone sarcomas, including various vaccines and cytokines, with limited success...
September 21, 2017: Oncologist
https://www.readbyqxmd.com/read/28934002/estimating-the-optimal-personalized-treatment-strategy-based-on-selected-variables-to-prolong-survival-via-random-survival-forest-with-weighted-bootstrap
#14
Jincheng Shen, Lu Wang, Stephanie Daignault, Daniel E Spratt, Todd M Morgan, Jeremy M G Taylor
A personalized treatment policy requires defining the optimal treatment for each patient based on their clinical and other characteristics. Here we consider a commonly encountered situation in practice, when analyzing data from observational cohorts, that there are auxiliary variables which affect both the treatment and the outcome, yet these variables are not of primary interest to be included in a generalizable treatment strategy. Furthermore, there is not enough prior knowledge of the effect of the treatments or of the importance of the covariates for us to explicitly specify the dependency between the outcome and different covariates, thus we choose a model that is flexible enough to accommodate the possibly complex association of the outcome on the covariates...
September 21, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28933270/11c-choline-pet-ct-based-helical-tomotherapy-as-treatment-approach-for-bone-metastases-in-recurrent-prostate-cancer-patients
#15
Elena Incerti, Vincenzo Gangemi, Paola Mapelli, Chiara Lucrezia Deantoni, Giampiero Giovacchini, Federico Fallanca, Andrei Fodor, Andrea Ciarmiello, Sergio Baldari, Luigi Gianolli, Nadia Di Muzio, Maria Picchio
To evaluate the efficacy of 11C-choline PET/CT (CHO-PET/CT) based helical tomotherapy (HTT) as a therapeutic approach for bone metastases in recurrent prostate cancer (PCa) patients. METHODS This retrospective study includes 20 PCa patients (median age: 67; range: 51-80 years) presenting biochemical relapse after primary treatment who underwent CHO-PET/CT based HTT on positive bone metastases from December 2007 to June 2014. The effectiveness of HTT assessed with biochemical response at 3/6/12 months, biochemical relapse free survival (bRFS) and overall survival (OS) at 2 years...
September 19, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28932949/twenty-first-century-cancer-patterns-in-small-island-nations-grenada-and-the-english-speaking-caribbean
#16
Lindsay M Cattin, Paulo S Pinheiro, Karen E Callahan, Robert Hage
PURPOSE: Grenada is a small island nation of 105,000 in the Caribbean with one single general hospital and pathology laboratory. This study assesses cancer incidence on the island based on existing pathology reports, and compares the cancer mortality burden between Grenada and other Caribbean nations. METHODS: Age-adjusted overall and site-specific cancer "incidence" rates (based on pathology reports) and mortality rates were calculated and compared for 2000-2009...
September 20, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28931292/-salvage-lymph-node-dissection-in-radical-prostatectomy-failure-a-case-study
#17
N Marečková, M Staník, D Macík, J Doležel
Salvage lymph node dissection is a therapeutic option in patients with nodal-only recurrence after radical prostatectomy. Although this operation does not achieve a complete cure in the majority of cases, it can prolong survival and help postpone hormonal therapy in selected patients while being a relatively safe procedure. The authors describe a case study of a radical prostatectomy patient with radiologically proven recurrence of prostate cancer limited to an internal iliac node. He underwent salvage lymph node dissection with a complete biochemical response...
2017: Rozhledy V Chirurgii: Měsíčník Československé Chirurgické Společnosti
https://www.readbyqxmd.com/read/28930697/overexpression-of-muc1-and-genomic-alterations-in-its-network-associate-with-prostate-cancer-progression
#18
Xiaozeng Lin, Yan Gu, Anil Kapoor, Fengxiang Wei, Tariq Aziz, Diane Ojo, Yanzhi Jiang, Michael Bonert, Bobby Shayegan, Huixiang Yang, Khalid Al-Nedawi, Pierre Major, Damu Tang
We investigate the association of MUC1 with castration-resistant prostate cancer (CRPC), bone metastasis, and PC recurrence. MUC1 expression was studied in patient-derived bone metastasis and CRPCs produced by prostate-specific PTEN(-/-) mice and LNCaP xenografts. Elevations in MUC1 expression occur in CRPC. Among nine patients with hormone-naïve bone metastasis, eight express MUC1 in 61% to 100% of PC cells. Utilizing cBioPortal PC genomic data, we organized a training (n=300), testing (n=185), and validation (n=194) cohort...
September 17, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28930600/line-1-as-a-therapeutic-target-for-castration-resistant-prostate-cancer
#19
Nadine Houede, Pier Vincenzo Piazza, Philippe Pourquier
Prostate cancer is the third leading cause of death by cancer in men. Surgery or hormone deprivation usually contains the progression of the local forms of the disease. In metastatic situations, chemotherapy or second generation hormone therapies are used with an overall survival that never exceeds 36 months when tumors become resistant to castration. In the search for new alternatives, clinical trials with various classes of anticancer drugs have been performed, including chemotherapies, targeted therapies with kinase inhibitors, radium-223, or immunotherapies with somehow limited efficacy...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28929037/risk-of-death-from-prostate-cancer-with-and-without-definitive-local-therapy-when-gleason-pattern-5-is-present-a-surveillance-epidemiology-and-end-results-analysis
#20
Jonathan Frandsen, Andrew Orton, Dennis Shrieve, Jonathan Tward
Purpose The purpose is to evaluate the patterns of care and comparative effectiveness for cause-specific and overall survival of definitive local treatments versus conservatively managed men with a primary or secondary Gleason pattern of 5. Methods and materials Patients diagnosed from 2004 to 2012 with a primary or secondary Gleason pattern of 5 N0M0 prostate cancer were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier and Cox regression analyses were used to estimate the survival...
July 10, 2017: Curēus
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"